Skip to main
BCAX

BCAX Stock Forecast & Price Target

BCAX Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 40%
Buy 30%
Hold 30%
Sell 0%
Strong Sell 0%

Bulls say

Bicara Therapeutics is a clinical-stage biopharmaceutical company, with a focus on developing important therapies for people living with cancer. Investors can look forward to additional data from ficerafusp alfa in 1L HPV- HNSCC and in 3L+ mCRC, as well as other upcoming catalysts such as presentation of long-term follow-up data from Phase 1b study of ficerafusp alfa + Keytruda in 1L R/M HPV-negative HNSCC and data from Phase 1b expansion cohort in 2H26. Additionally, Bicara's CRC program has the potential to recruit approximately 40 patients across two cohorts and remains a signal-seeking effort. However, in our bullish case, we project the company's stock to achieve increased prices, reflecting the potential success of their innovative treatments.

Bears say

Bicara Therapeutics is a Boston-based biotech company focused on developing bifunctional antibody therapies for cancer treatment. Despite the potential for success with ficerafusp alfa, there are significant risks due to its early stage in clinical trials and competition in the oncology market. Despite promising financials and expected milestones, investors should approach with caution due to the inherent risks involved in biotech companies and an already saturated market.

BCAX has been analyzed by 10 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 30% recommend Buy, 30% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Bicara Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Bicara Therapeutics Inc (BCAX) Forecast

Analysts have given BCAX a Buy based on their latest research and market trends.

According to 10 analysts, BCAX has a Buy consensus rating as of May 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $29.40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $29.40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Bicara Therapeutics Inc (BCAX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.